Semaglutide, found in drugs like Ozempic and Wegovy, has been associated with an increased risk of nonarteritic anterior ischemic optic neuropathy (NAION), a rare condition causing sudden vision loss, according to multiple studies. Researchers from institutions like Massachusetts Eye and Ear Hospital have observed a rise in NAION cases among patients taking semaglutide. While the exact mechanism remains unclear, patients with diabetes and obesity seem to be more susceptible. Novo Nordisk, the maker of these drugs, acknowledges the findings but highlights the need for further research to establish a direct link. Despite the potential risk, semaglutide continues to be a key component of treatments for diabetes and obesity, showcasing its multifaceted impact on various health conditions.